Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Faron Pharmaceuticals Oy ( (GB:FARN) ) just unveiled an update.
Faron Pharmaceuticals has registered 909,517 new shares in the Finnish Trade Register following the exercise of an equal number of special rights, raising approximately EUR 1.55 million in aggregate subscription proceeds. The new shares rank pari passu with existing shares, bringing the company’s total ordinary shares to 119,472,660, of which 3,688,699 are held in treasury and do not carry shareholder rights, resulting in 115,783,961 voting rights; trading of the new shares on Nasdaq First North and AIM is expected to begin around 5 February 2026, modestly expanding Faron’s equity base and potentially improving liquidity in its stock while providing additional capital to support its clinical-stage immuno-oncology pipeline.
More about Faron Pharmaceuticals Oy
Faron Pharmaceuticals Ltd, based in Turku, Finland, is a global clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat cancer. Its lead asset, bexmarilimab, is a humanized anti-Clever-1 antibody designed to reduce cancer-related immunosuppression by reprogramming myeloid cells and is currently being evaluated in Phase I/II trials for hematological cancers in combination with standard treatments.
For a thorough assessment of FARN stock, go to TipRanks’ Stock Analysis page.